Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent immune plasma for COVID-19 in Ecuador
ISRCTN85216856Phase 3Completed
- Sponsor
- Universidad UTE
- Start
- May 2020
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard therapy + convalescent immune plasma with Standard therapy + non-immune plasma (2 arms). Primary endpoint: Case fatality rate. Started May 2020; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)non-immune plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN85216856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85216856.